These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22296623)

  • 61. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
    Liu N; Huang H; Xu L; Hua X; Li X; Liu S; Yang C; Zhao C; Zhao C; Li S; Dou QP; Liu J
    Toxicol Lett; 2014 Jan; 224(3):333-40. PubMed ID: 24291039
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
    Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
    Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
    Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
    Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of the protein ubiquitination response induced by Doxorubicin.
    Mandili G; Khadjavi A; Gallo V; Minero VG; Bessone L; Carta F; Giribaldi G; Turrini F
    FEBS J; 2012 Jun; 279(12):2182-91. PubMed ID: 22536838
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
    Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF
    Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
    Brem GJ; Mylonas I; Brüning A
    Gynecol Oncol; 2013 Feb; 128(2):383-90. PubMed ID: 23107612
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
    Taylor-Harding B; Agadjanian H; Nassanian H; Kwon S; Guo X; Miller C; Karlan BY; Orsulic S; Walsh CS
    Br J Cancer; 2012 Jan; 106(2):333-43. PubMed ID: 22166800
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
    Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells.
    Yerlikaya A; Altıkat S; Irmak R; Cavga FZ; Kocacan SA; Boyaci I
    Mol Med Rep; 2013 Jul; 8(1):277-81. PubMed ID: 23660746
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
    Carew JS; Medina EC; Esquivel JA; Mahalingam D; Swords R; Kelly K; Zhang H; Huang P; Mita AC; Mita MM; Giles FJ; Nawrocki ST
    J Cell Mol Med; 2010 Oct; 14(10):2448-59. PubMed ID: 19583815
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
    Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
    Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
    Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chauhan D; Baccarani M; Cavo M; Anderson KC
    Leukemia; 2009 Sep; 23(9):1679-86. PubMed ID: 19369963
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
    Kawabata S; Gills JJ; Mercado-Matos JR; Lopiccolo J; Wilson W; Hollander MC; Dennis PA
    Cell Death Dis; 2012 Jul; 3(7):e353. PubMed ID: 22825471
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
    PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
    Eriksson E; Wickström M; Perup LS; Johnsen JI; Eksborg S; Kogner P; Sävendahl L
    J Natl Cancer Inst; 2014 Mar; 106(3):djt459. PubMed ID: 24586107
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The dynamics of histone H2A ubiquitination in HeLa cells exposed to rapamycin, ethanol, hydroxyurea, ER stress, heat shock and DNA damage.
    Nakata S; Watanabe T; Nakagawa K; Takeda H; Ito A; Fujimuro M
    Biochem Biophys Res Commun; 2016 Mar; 472(1):46-52. PubMed ID: 26898798
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress.
    Asano T; Sato A; Isono M; Okubo K; Ito K; Asano T
    Biomed Rep; 2015 Nov; 3(6):797-801. PubMed ID: 26623018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.